U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824155) titled 'HEAT Trial (HER2 Antibody Therapy with Lutetium-177)' on Feb. 07.
Brief Summary: This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
HER2 Gene Mutation
Advanced Solid Tumors
Intervention:
DRUG: 177Lu-RAD202
177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
Recruitment ...